إعلان
إعلان
PTGX
Protagonist Therapeutics, Inc
87.21
USDبرعاية
-0.13
-0.15%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
85.20
-2.01
-2.31%
تقارير أرباح PTGX
النسبة الإيجابية المفاجئة
PTGX تفوق 23 من 38 آخر التقديرات.
61%
التقرير التالي
بيانات التقرير القادم
١٩ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$9.10M
/-$0.61
التغير الضمني من Q3 25 (Revenue/ EPS)
+93.22%
/-1.61%
التغير الضمني من Q4 24 (Revenue/ EPS)
-94.66%
/-130.81%
Protagonist Therapeutics, Inc earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, PTGX reported earnings of -0.62 USD per share (EPS) for Q3 25, beating the estimate of -0.65 USD, resulting in a 4.88% surprise. Revenue reached 4.71 مليون, compared to an expected 3.71 مليون, with a 27.04% difference. The market reacted with a -0.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 9.10 مليون USD, implying an decrease of -1.61% EPS, and increase of 93.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Protagonist Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Protagonist Therapeutics, Inc reported EPS of -$0.62, beating estimates by 4.88%, and revenue of $4.71M, 27.04% above expectations.
How did the market react to Protagonist Therapeutics, Inc's Q3 2025 earnings?
The stock price moved down -0.3%, changed from $79.78 before the earnings release to $79.54 the day after.
When is Protagonist Therapeutics, Inc expected to report next?
The next earning report is scheduled for ١٩ فبراير ٢٠٢٦.
What are the forecasts for Protagonist Therapeutics, Inc's next earnings report?
Based on 15
analysts, Protagonist Therapeutics, Inc is expected to report EPS of -$0.61 and revenue of $9.10M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان